The stock of Revolution Medicines Inc. (NASDAQ:RVMD) increased by $0.18 on Friday to finish at $29.99, up 0.60 percent. The last five days have seen an average of 971,980 shares of common stock traded. 7 times new highs were reached in the current year, with a gain of $6.17. The average number of shares traded over the last 20 days was 1,241,145, while the average volume over the last 50 days totaled 1,149,092.
RVMD stock appreciated 13.04% since last month. On 08/01/23, the company’s shares reached a one-month low of $24.61. The stock touched a high of $33.19 on 08/03/23, after rallying from a low of $17.03 in 52 weeks. The price of RVMD stock has risen by 25.90% or $6.17 this year, reaching a new high 7 times. Still, the stock price is down -9.64% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
RVMD stock investors should be aware that Revolution Medicines Inc. (RVMD) stock had its last reported insider trading activity 12 days ago on Aug 02. On Aug 02, Kelsey Stephen Michael sold 16,666 shares at $32.40 each. This transaction resulted in the insider making $539,978. On Aug 01, Kelsey Stephen Michael sold 16,666 shares at a price of US$29.19. After the transaction, the insider now owns 309,114 shares. General Counsel Cislini Jeff had earlier sold 1,500 shares on Jul 31 for $26.02 a share. The transaction was completed for $39,030.
Valuation Metrics
Beta for the stock is 1.38. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 110.32, the price-to-book (PB) ratio of 3.44.
Financial Health
For the recent quarter, Revolution Medicines Inc.’s quick ratio was 11.80, while its current ratio was 11.80, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $293.66 million and revenue of $35.38 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. RVMD’s return on assets (ROA) during the last 12 months has been -31.30%. There was a -37.60% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -36.50%.
Earnings Surprise
A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $3.82 million, while revenues fell by -138.74% to $7.01 million. EBITDA was -$111.88 million for the quarter. At the end of Revolution Medicines Inc.’s most recent quarter, its liabilities totaled 142.87 million, while its total debt was $63.26 million. Equity owned by shareholders amounts to $109.17 million.
Technical Picture
Here’s a quick look at Revolution Medicines Inc.’s (RVMD) price momentum from a technical perspective. As of 11 August, the RSI 9-day stood at 58.51%, suggesting the stock is Neutral, with a 101.71% historical volatility rate.
The stochastic %K and %D were 60.57% and 60.81% respectively, while the average true range (ATR) was 1.33. Based on the 14-day stochastic reading of 62.70%, the RSI (14) reading is 59.31%. On the 9-day MACD Oscillator, the stock is at -0.93, and the 14-day reading is at 0.89.
Analyst Ratings
In its most recent analyst report, JP Morgan raised its rating on Revolution Medicines Inc. (NASDAQ: RVMD) to an Overweight. Prior to this, analysts firm rated the stock as a Neutral.
